Functional Annotation of ESR1 Gene Fusions in Estrogen Receptor-Positive Breast Cancer by Lei, J.T. et al.
Functional Annotation of ESR1 Gene Fusions in Estrogen 
Receptor-Positive Breast Cancer
Jonathan T. Lei1,2,24, Jieya Shao3,4,24, Jin Zhang5,6,24, Michael Iglesia3,24, Doug W. Chan1, 
Jin Cao7, Meenakshi Anurag1, Purba Singh1, Xiaping He8, Yoshimasa Kosaka9, Ryoichi 
Matsunuma10, Robert Crowder3, Jeremy Hoog3, Chanpheng Phommaly3, Rodrigo 
Goncalves11, Susana Ramalho12, Raquel Mary Rodrigues Peres12, Nindo Punturi1, Cheryl 
Schmidt1, Alex Bartram13, Eric Jou13, Vaishnavi Devarakonda1, Kimberly R. Holloway1, W. 
Victoria Lai14, Oliver Hampton15, Anna Rogers3, Ethan Tobias16, Poojan A. Parikh17, Sherri 
R. Davies3, Shunqiang Li3, Cynthia X. Ma3, Vera J. Suman18, Kelly K. Hunt19, Mark A. 
Watson20, Katherine A. Hoadley8, E. Aubrey Thompson21, Xi Chen7, Shyam M. Kavuri1, 
Chad J. Creighton22, Christopher A. Maher3,23, Charles M. Perou8, Svasti Haricharan1, and 
Matthew J. Ellis1,2,7,25,*
1Department of Medicine, Lester and Sue Smith Breast Center, Baylor College of Medicine, 
Houston, TX 77030, USA
2Interdepartmental Graduate Program in Translational Biology and Molecular Medicine, Baylor 
College of Medicine, Houston, TX 77030, USA
3Department of Medicine, Washington University in St. Louis, St. Louis, MO 63110, USA
4Siteman Cancer Center, Washington University in St. Louis, St. Louis, MO 63110, USA
5Cancer Biology Division, Department of Radiation Oncology, Washington University in St. Louis, 
St. Louis, MO 63110, USA
6Institute for Informatics (I2), Washington University in St. Louis, St. Louis, MO 63110, USA
7Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, 
USA
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
*Correspondence: mjellis@bcm.edu.
AUTHOR CONTRIBUTIONS
Conceptualization, M.J.E.; Methodology, M.J.E., S.L., P.S., J.S., J.C., X.C., S.H., and J.T.L.; Software, C.M.P., C.A.M., J.Z., and 
K.A.H.; Validation, J.T.L. and P.S.; Formal Analysis, J.Z., M.I., M.A., C.J.C., K.A.H., O.H., K.K.H., J.H., J.T.L., and V.D.; 
Investigation, J.T.L., J.S., J.Z., M.I., D.W.C., J.C., M.A., P.S., X.H., Y.K., R.M., J.H., A.R., C.P., R.G., R.C., S.R., R.M.R.P., N.P., C.S., 
A.B., E.J., W.V.L., E.T., P.A.P., E.A.T., and V.D.; Resources, M.J.E. and C.X.M.; Data Curation, C.X.M., K.A.H., V.J.S., C.M.P., 
K.K.H., M.A.W., and E.A.T.; Writing – Original Draft, M.J.E., J.S., S.H., and J.T.L.; Writing – Review & Editing, M.J.E., S.H., J.S., 
S.M.K., J.T.L., and K.R.H.; Visualization, J.S., J.Z., M.I., D.W.C., A.B., and J.T.L.; Supervision, M.J.E., C.M.P., S.H., S.M.K., and 
R.K.H.; Project Administration, M.J.E., S.R.D., and K.R.H.; Funding Acquisition, M.J.E., C.M.P., S.L., J.S., S.M.K., C.A.M., E.A.T., 
R.C., and V.S.
DECLARATION OF INTERESTS
M.J.E. received ad hoc consulting fees from Pfizer, AstraZeneca, Celgene, NanoString, Puma, and Novartis. C.X.M. received research 
funding and ad hoc consulting fees from Pfizer and Novartis. C.M.P. and M.J.E. are equity stock holders, consultants, and Board of 
Directors members of BioClassifier, inventor on a patent for the Breast PAM50 assay. All other authors declare no competing of 
interests.
SUPPLEMENTAL INFORMATION




Cell Rep. Author manuscript; available in PMC 2018 October 04.
Published in final edited form as:













8Department of Genetics, Lineberger Comprehensive Cancer Center, University of North 
Carolina, Chapel Hill, NC 27599, USA
9Department of Breast and Endocrine Surgery, Kitasato University School of Medicine, 
Sagamihara, Kanagawa 252-0375, Japan
10First Department of Surgery, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka 
431-3192, Japan
11Department of Obstetrics and Gynecology, University of São Paulo School of Medicine 
(FMUSP), Cerqueira César, São Paulo 01246-903, Brazil
12Department of Obstetrics and Gynecology, Faculty of Medical Science, State University of 
Campinas - UNICAMP, Campinas, São Paulo 13083-970, Brazil
13Queens’ College, University of Cambridge, Cambridge CB3 9ET, UK
14Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer 
Center, New York, NY 10065, USA
15Human Genome Sequencing Center, Department of Molecular and Human Genetics, Baylor 
College of Medicine, Houston, TX 77030, USA
16University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
17School of Medicine, Baylor College of Medicine, Houston, TX 77030, USA
18Alliance Statistical Center, Mayo Clinic, Rochester, MN 55905, USA
19Department of Breast Surgical Oncology, MD Anderson Cancer Center, Houston, TX 77030, 
USA
20Department of Pathology and Immunology, Washington University in St. Louis, St. Louis, MO 
63110, USA
21Department of Cancer Biology, Mayo Clinic Comprehensive Cancer Center, Jacksonville, FL 
32224, USA
22Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA
23The McDonnell Genome Institute, Washington University in St. Louis, St. Louis, MO 63108, 
USA
24These authors contributed equally
25Lead Contact
SUMMARY
RNA sequencing (RNA-seq) detects estrogen receptor alpha gene (ESR1) fusion transcripts in 
estrogen receptor-positive (ER+) breast cancer, but their role in disease pathogenesis remains 
unclear. We examined multiple ESR1 fusions and found that two, both identified in advanced 
endocrine treatment-resistant disease, encoded stable and functional fusion proteins. In both 
examples, ESR1-e6>YAP1 and ESR1-e6>PCDH11X, ESR1 exons 1–6 were fused in frame to C-
terminal sequences from the partner gene. Functional properties include estrogen-independent 
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growth, constitutive expression of ER target genes, and anti-estrogen resistance. Both fusions 
activate a metastasis-associated transcriptional program, induce cellular motility, and promote the 
development of lung metastasis. ESR1-e6>YAP1- and ESR1-e6>PCDH11X-induced growth 
remained sensitive to a CDK4/6 inhibitor, and a patient-derived xenograft (PDX) naturally 
expressing the ESR1-e6>YAP1 fusion was also responsive. Transcriptionally active ESR1 fusions 
therefore trigger both endocrine therapy resistance and metastatic progression, explaining the 
association with fatal disease progression, although CDK4/6 inhibitor treatment is predicted to be 
effective.
In Brief
Lei et al. show that transcriptionally active estrogen receptor gene (ESR1) fusions identified from 
late-stage, treatment-refractory estrogen receptor-positive (ER+) breast cancer drive pan-endocrine 
therapy resistance and metastatic progression. Growth of breast tumors driven by ESR1 fusions at 
primary and metastatic sties can be suppressed with a CDK4/6 inhibitor.
Graphical Abstract
INTRODUCTION
The etiology of endocrine therapy resistance in estrogen receptor-positive (ER+) breast 
cancer is complex (Ma et al., 2015) but includes acquired somatic mutations within the 
ligand-binding domain (LBD) of the estrogen receptor gene (ESR1) causing ligand-
independent activation (Pejerrey et al., 2018). RNA sequencing (RNA-seq) has also 
identified multiple ESR1 gene fusion events, but their role in endocrine therapy resistance 
and how they might be targeted therapeutically is unclear (Giltnane et al., 2017). The 
majority of ESR1 fusion transcripts have been identified in primary breast cancer, and in 
some of these instances patients have high-grade disease and/or resistance to endocrine 
therapy (Giltnane et al., 2017; Veeraraghavan et al., 2014), implying some functionality. In 
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some cases, up to five ESR1 coding exons are included (exons 3–7), mostly fused out of 
frame but occasionally, and more interestingly, in frame. However, detailed characterization 
of the predicted chimeric proteins and a clear demonstration of a causal role for ESR1 
fusions in endocrine therapy resistance have been largely lacking.
Several years ago, our group described an unequivocal stable and functional ESR1 fusion 
protein (Li et al., 2013). This was an in-frame fusion gene consisting of exons 1–6 of ESR1 
fused to C-terminal sequences from the Hippo pathway coactivator YAP1 (ESR1-e6>YAP1), 
identified in a metastatic sample and matched patient-derived xenograft (PDX) from a 
patient with endocrine therapy-resistant disease. Limited functional characterization of 
ESR1-e6>YAP1 showed that the fusion protein drove resistance to endocrine therapy and 
estradiol-independent proliferation. Herein we build on our original report by contrasting the 
functional, transcriptional, and pharmacological properties of the ESR1-e6>YAP1 fusion 
with additional ESR1 gene fusion events identified by RNA-seq of both early-stage and 
metastatic ER+ breast cancers.
RESULTS
Identification and Verification of In-Frame ESR1 Gene Fusions
A systematic screen was conducted to identify ESR1 translocations in three datasets: 728 
primary breast tumors from The Cancer Genome Atlas (TCGA) (Ciriello et al., 2015), 81 
primary breast cancers from two neoadjuvant aromatase inhibitor (AI) clinical trials (Ellis et 
al., 2011; Olson et al., 2009), and 25 biopsy samples from patients with late-stage ER+ 
breast cancer (Figure 1A). From these analyses, 13 high-confidence ESR1 fusion transcripts 
were identified in 10 ER+ samples from the TCGA dataset (Table S1). Five of these fusion 
events were between ESR1 and CCDC170 and were recently reported (Veeraraghavan et al., 
2014). Of these, only 1 CCDC170 out-of-frame fusion included exon 5 (e5) of ESR1 
(ESR1-e5>CCDC170), thereby preserving sufficient ESR1 sequence to bind DNA. A single 
TCGA case displayed evidence for three ESR1 gene fusions: (1) a PCR-validated ESR1-e6 
fused in frame to C-terminal sequences from AKAP12 (ESR1-e6>AKAP12) (Figure S1); (2) 
a PCR-validated in-frame ESR1-e7 fusion involving the entire coding sequence of POLH, a 
DNA polymerase in the xeroderma pigmentosum gene family (ESR1-e7>POLH), and (3) an 
out-of-frame ESR1-e4>CCDC170 fusion.
From an RNA-seq screen of 81 primary, treatment-naive, ER+ breast cancers from two 
neoadjuvant AI clinical trials (Table S1, NeoAI Trials), two PCR-validated ESR1 fusions 
were identified. The first was an in-frame fusion retaining the first six exons of ESR1 
(ESR1-e6) fused to C-terminal sequences of NOP2, a nucleolar protein (ESR1-e6>NOP2). 
The second fusion identified involved ESR1-e6 fused out of frame to AKR1D1, an aldo-keto 
reductase family member (ESR1-e6>AKR1D1). In the datasets of primary ER+ breast 
cancer examined, ESR1 fusion events are relatively rare, occurring at ~2% frequency. The 
majority of these fusions are out of frame, and 42% of these fusion events (8 of 19) include 
sufficient ESR1 exons to allow ESR1 -specific nuclear binding.
To investigate ESR1 fusion events in late-stage ER+ disease, RNA-seq data from 25 biopsy 
samples obtained from patients with advanced endocrine therapy refractory disease were 
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examined (Table S1, Late Stage, and Table S2). These samples included the ESR1-e6>YAP1 
sample we originally described, as it was drawn from this series (Li et al., 2013), and of 
these 25 samples, 2 harbored in-frame ESR1 fusion events. The ESR1-e6>PCDH11X fusion 
was caused by ESR1-e6 fusion in frame with C-terminal sequences of protocadherin 11X. 
PCDH11X encodes for an atypical cell surface cadherin family member. The sample was a 
chest wall recurrence from a 49-year-old man who presented with locally advanced ER+ 
breast cancer and experienced progression on tamoxifen, letrozole/leuprolide, and 
fulvestrant before the sample was accrued.
Of the eight identified ESR1 fusions from all datasets that were PCR validated (Figure S1), 
only three in-frame fusions, ESR1-e6>YAP1 and ESR1-e6>PCDH11X from advanced 
disease and ESR1-e6>NOP2 from a primary tumor that showed subsequent resistance to 
endocrine therapy, produced stable proteins when expressed as cDNA, allowing further 
study (Figure 1B). Expression of all three fusion partner genes were highly expressed in 
patient tumors, as shown by expression rank plots for YAP1, PCDH11X, and NOP2 
translocation-bearing tumors relative to the expression of these genes among TCGA breast 
samples (Figure 1C). Relative RNA levels of transcripts were analyzed for each fusion 
partner, which showed increases in transcript levels beyond the fusion breakpoint for each 
gene examined, confirming that the fusion partner was disproportionately expressed versus 
the non-translocated allele (Figure 2A).
In-Frame ESR1 Fusions from Endocrine-Refractory Disease Confer Estrogen-Independent 
and Fulvestrant-Resistant Growth of ER+ Breast Cancer Cells
To test whether examples of ESR1 in-frame gene fusions were drivers of endocrine therapy 
resistance, each fusion was individually expressed in two ER+ breast cancer cell line models: 
T47D and MCF7. Expression of fusion ER proteins in T47D cells was similar or lower than 
that observed in the WHIM18 PDX bearing the ESR1-e6>YAP1 fusion, indicating that 
phenotypic conclusions are not based on excess expression (Figure 2B). In addition, several 
out-of-frame CCDC170 and an AKR1D1 fusion event identified in this study (Table S1) 
were also engineered into T47D cells. Growth of ESR1 fusion-expressing T47D was 
monitored in estradiol (E2)-deprived media and after addition of E2. Both in-frame fusions 
from advanced disease, ESR1-e6>YAP1 and ESR1-e6>PCDH11X, promoted estrogen-
independent growth (Figure 2C, −E2), but the primary tumor fusion event, ESR1-e6>NOP2, 
had no growth-promoting properties. The out-of-frame events tested were also inactive 
(Figure S2A). E2 could stimulate growth in all conditions of fusion construct expression 
(Figure 2C, compare +E2 and −E2), suggesting that neither the ESR1 in-frame active 
fusions (ESR1-e6>YAP1 and ESR1-e6>PCDH11X) nor the ESR1-e6 truncation, and not 
even the in-frame but inactive ESR1-e6>NOP2 fusion, could function as a dominant-
negative on endogenous ER. Cells were treated with fulvestrant to degrade endogenous ER, 
while retaining expression of intact ESR1 fusions that cannot bind drug or ligand, to test the 
specific contribution of the fusions to E2-independent growth. As expected, endogenous ER 
was degraded by fulvestrant, whereas levels of ESR1 fusion proteins, as well as an ESR1-e6 
truncation construct, were unaffected (Figure S2B), and growth promoted by ESR1-
e6>YAP1 and ESR1-e6>PCDH11X was resistant to fulvestrant treatment (Figure 2C, −E2, 
+Fulvestrant). There was lack of additional growth promotion by the fusions when E2 was 
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added in the presence of fulvestrant (Figure 2C, compare +E2, +Fulvestrant and −E2, 
+Fulvestrant). However, under these same conditions (Figure 2C, +E2, +Fulvestrant), 
growth induced by the YAP1 and PCDH11X fusions remains significantly greater than 
controls (YFP and ESR1-WT [wild-type]). These results were confirmed in a second ER+ 
breast cancer cell line, MCF7 (Figures S2C-S2D). The NOP2 fusion was highly expressed in 
the MCF7 cell line, in contrast to NOP2 fusion-expressing T47D, but still lacked growth-
promoting activity in hormone-deprived conditions, confirming that absence of functional 
effects was not due to inadequate expression of the NOP2 fusion.
The ability of the three ESR1-e6-containing in-frame fusions to induce estrogen-
independent growth was further tested in vivo in a xenograft study with stable T47D cells 
without supplementary E2. As controls, T47D YFP cells were used with supplementary E2. 
Results showed that control YFP −E2 cells produced negligible tumor growth compared 
with YFP cells +E2 (Figure 2D). However, T47D cells expressing YAP1 and PCDH11X in-
frame ESR1 fusions formed tumors significantly larger than YFP −E2, while the cells 
expressing the NOP2 fusion did not (Figure 2D).
Active ESR1 Fusions Promote Estrogen-Independent Gene Expression
To explore transcriptional properties associated with the ESR1 fusion proteins described 
above, genome-wide binding of HA-tagged ESR1 fusions was examined by HA chromatin 
immunoprecipitation followed by next-generation sequencing (ChIP-seq) in hormone-
deprived stable T47D. ChIP-seq identified 445 binding regions shared by ESR1-WT, ESR1-
e6>YAP1, and ESR1-e6>PCDH11X (Figure 3A). Very few sites were bound by ESR1-
e6>NOP2 fusion despite high expression of HA-tagged NOP2 fusion (Figure S3E), 
supporting earlier observations of inactivity in functional studies (Figures 2C, 2D, and S2C). 
ChIP-qPCR confirmed recruitment of ER to regulatory regions of known estrogen-
responsive genes in a ligand-dependent manner in cells expressing WT-ER (Figure 3B). 
Additionally, both YAP1 and PCDH11X fusions showed estrogen-independent enrichment 
at regulatory regions of established estrogen-responsive genes. For example, both fusions 
were enriched at the promoter of a canonical ER-regulated gene, GREB1, and the 
PDCH11X fusion was also enriched at enhancer estrogen response elements (EREs) of 
TFF1 and PGR (Figure 3B).
To investigate whether expression from genes bound by ESR1 fusions was modulated, RNA-
seq was performed. Hierarchical clustering was conducted on differentially expressed genes 
near 445 shared sites bound by ESR1-WT, YAP1, and PCDH11X fusions, as indicated by 
the ChIP-seq data (Figure 3C). Upon stimulation with E2, the expression pattern of YFP 
control cells clustered away from unstimulated YFP cells, with enrichment for differential 
expression of estrogen-responsive genes. The YAP1 and PCDH11X fusion-expressing cells 
had expression patterns that clustered together under estrogen-deprived and stimulated 
conditions and with E2-stimulated YFP cells. The transcriptionally active ESR1 fusions 
maintained expression of estrogen-regulated genes in low-estrogen conditions at levels 
observed in YFP control cells in the presence of E2, demonstrating strong estrogen-
independent gene activation. mRNA-qPCR validation of GREB1, TFF1, and PGR 
expression confirmed estrogen-independent and fulvestrant-resistant gene regulation 
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(Figures 3D and S3F), suggesting that the active ESR1 fusions drive endocrine resistance in 
a canonical manner through ERE-dependent activation. Moreover, the estrogen-independent 
activity of the YAP1 and PCDH11X fusions was also independent of endogenous WT-ER, as 
transcriptional activity was maintained after cells were treated with fulvestrant to degrade 
endogenous ER. Thus, functionally important heterodimer formation between ESR1 fusion 
protein and WT-ER is not likely. This conclusion was also supported by the lack of ESR1 
fusion association with WT-ER in a co-immunoprecipitation assay (Figure S3D). In contrast, 
the ESR1-e6 truncation mutant and NOP2 fusion clustered together with YFP control cells 
displaying similar patterns of ligand-dependent ER gene expression, supporting our earlier 
observations that the NOP2 fusion lacks ability to bind a large repertoire of EREs but whose 
inactivity is not due to mis-localization outside the nucleus, as staining for HA-tagged ESR1 
fusions constructs demonstrated nuclear localization (Figure S3A). These data were further 
supported by ERE-luciferase reporter experiments in HEK293T cells (Figure S3B). ESR1-
WT drove estrogen-dependent expression of the ERE-luciferase reporter. In contrast, both 
ESR1-e6>YAP1 and ESR1-e6>PCDH11X as well as the ESR1-Y537S activating mutant 
drove estrogen-independent expression of the ERE-luciferase reporter. The level of 
activation by ESR1-e6>YAP1 was substantially higher than ESR1-e6> PCDH11X, which 
had activity intermediate to that achieved by the constitutively active ESR1-Y537S mutant 
and ESR1-e6>YAP1 (Li et al., 2013). In contrast to the ESR1-e6>YAP1 and ESR1-
e6>PCDH11X fusions, neither the ESR1-e6 truncation mutation nor the ESR1-e6>NOP2 
fusion drove expression of the ERE reporter. The transcriptional inactivity of the NOP2 
fusion was not due to abrogation of ERE binding, as pulldown experiments with a 
biotinylated concatenated ERE probe with a mutant ERE as a control demonstrated 
sequence-specific binding for all in-frame fusions (Figure S3C). In summary, our 
observations suggest that the inactivity of the NOP2 fusion may be due to a failure to access 
chromatin in the nucleus of intact cells, rather than an inability to bind DNA per se.
Active ESR1 Fusions Promote Metastasis by Upregulating an EMT-like Transcriptional 
Program
A cluster of genes was identified that was selectively upregulated by the active YAP1 and 
PCDH11X fusions (Figures 3C and4A). Gene set enrichment analysis (GSEA) was used to 
examine pathway enrichment in this cluster, which indicated significant enrichment of 
estrogen response pathways as well as an epithelial-to-mesenchymal transition (EMT)-like 
signature (Figure 4B). The EMT signature included TGM2, COL3A1, INHBA, and VCAN. 
One of the best-described EMT genes, SNAI1, was also selectively upregulated by both 
active fusions. Analysis of binding site distances to transcription start sites (TSSs) of genes 
in this cluster demonstrated that the majority of binding occurs at distances >50 kb from the 
TSS (Table S3). This suggests a propensity of the active YAP1 and PCDH11X fusions to 
bind in enhancer regions upstream and downstream of these genes, characteristic of the ER 
cistrome reported in the literature (Carroll et al., 2006). Motif analysis of these binding sites 
showed enrichment for the ERE motif (Figure S4A), suggesting that the direct regulation of 
EMT genes by the active YAP1 and PCDH11X fusions is mediated by enhancer and more 
distant range interactions. Upregulation of VCAN and SNAI1 transcripts (Figures 4C and 
S4B) and Snail protein (Figure 4D) was orthogonally validated. In MCF7 cells, whose basal 
levels of Snail were higher in YFP controls compared with T47D YFP, showed an induction 
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of Snail by ESR1-e6>YAP1, but not by ESR1-e6>PCDH11X, suggesting a degree of cell 
context-dependent effects (Figure 4D). Upregulation of Snail protein was also confirmed in 
T47D xenograft tumors and in a PDX model naturally harboring the ESR1-e6>YAP1 fusion 
(WHIM18) (Figure 4G). Expression of SNAI1 was unaffected by fulvestrant treatment in 
T47D cells, consistent with the conclusion that upregulation of EMT genes by the active 
fusions is independent of endogenous WT-ER (Figures 4C and S4B).
ChIP-seq also identified 71 selectively bound sites by ESR1-e6>YAP1 and ESR1-
e6>PCDH11X not bound by ESR1-WT nor ESR1-e6>NOP2 (Figure S4C). GSEA pathway 
analysis of differentially expressed genes near these sites showed enrichment for UV 
radiation response genes, as well as enrichment for EMT genes, with TGFBR3 and GJA1 
contributing to EMT pathway enrichment (Figure S4C). TGFBR3 encodes for transforming 
growth factor-β receptor III and has roles in migration and invasion (Gatza et al., 2010). 
GJA1 encodes for connexin-43, a gap junction protein whose expression in breast cancer 
cells has been implicated in pulmonary metastasis (Elzarrad et al., 2008), consistent with 
observed lung metastasis in both patients from which the ESR1-e6>YAP1 and ESR1-
e6>PCDH11X fusions were identified.
A decrease in E-cadherin levels from YAP1 and PCDH11X fusion-expressing cells was 
observed relative to YFP control and NOP2 fusion-expressing cells (Figure 4D), and a 
decrease in cell surface E-cadherin was also observed, consistent with an EMT-like 
transition (Figures S4E and S4F). However, there was no detectable increase in vimentin 
levels, suggesting that the YAP1 and PCDH11X fusions drive a partial EMT gene expression 
pattern that nonetheless can be metastasis associated (Jolly etal., 2015). To examine the 
functional consequences of the active fusions with respect to the metastatic process, cell 
motility was examined. The YAP1 and PCDH11X fusions induced significantly greater 
wound recovery and motility than YFP controls and NOP2 fusion-expressing cells (Figure 
4E, quantified in Figure S4D). To exclude the possibility that EMT-associated gene 
expression was due to phenotypic drift of cells under long-term selection, small interfering 
RNA (siRNA)-mediated knockdown of ESR1-e6>YAP1 fusion was examined to determine 
whether EMT-associated features could be reversed. Estrogen-deprived stable T47D YFP 
control or ESR1-e6>YAP1-expressing cells were pre-treated with fulvestrant to degrade 
endogenous WT-ER, before transfecting with negative control siRNA (siESR1–) or siESR1 
against the N terminus of ESR1 (siESR1+). Forty-eight hours post-transfection, Snail 
protein levels were markedly reduced in ESR1-e6>YAP1 cells after siESR1 transfection 
with or without fulvestrant pre-treatment compared with siESR1 – with or without 
fulvestrant (Figure 4F, compare lanes 5 and 7 with lanes 6 and 8). In addition, cells with 
decreased Snail as a result of ER-YAP1 fusion protein knockdown tended to have higher 
levels of E-cadherin, suggesting that knockdown of the ESR1-e6>YAP1 fusion transcript 
restores these aspects of a typical epithelial gene expression pattern. Similar effects were 
confirmed in stable MCF7 cells expressing ESR1-e6>YAP1 (Figure S4G, compare lanes 5 
and 7 with lanes 6 and 8), although Snail levels were more affected by fulvestrant pre-
treatment alone, showing that higher basal levels of Snail in MCF7 cells can also be driven 
by WT ESR1 (Figure S4G, compare lanes 1 and 3 for YFP-expressing cells and lanes 5 and 
7 for ESR1-e6>YAP1-expressing cells). However, Snail expression is resistant to fulvestrant 
suppression in the presence of the ESR1-e6>YAP1 fusion (Figure S4G, compare lanes 3 and 
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7). The metastatic potential of fusion-expressing cells in vivo was measured by ER 
immunohistochemistry from the lungs, liver, and bones of mice bearing T47D xenografts 
from Figure 2D. The number of micrometastatic ER+ cells in the lungs of YAP1 and 
PCDH11X fusion bearing mice was significantly greater than that in the lungs of mice 
bearing tumors generated from YFP control cells upon estrogen deprivation (Figure 4H). 
YFP control tumors grown with E2 supplementation were much larger (Figure 2D), but 
pulmonary micrometastasis was not significantly different from YFP controls −E2, 
demonstrating that differences in pulmonary metastasis potential associated with the active 
fusions were not due simply to differences in disease burden. Bone and hepatic 
micrometastases were not observed. Pulmonary metastasis in this model was not a feature of 
YFP control cells, even when disease burden was increased markedly with E2 
supplementation. Taken together, these results suggest a role for active YAP1 and PCDH11X 
fusions in driving pulmonary metastasis in association with the expression of genes known 
to contribute to EMT biology and metastatic behavior.
Growth Driven by ESR1 Fusions Can Be Suppressed with CDK4/6 Inhibitor Treatment
The loss of the LBD renders the function of ESR1 fusion genes resistant to all endocrine 
treatments, and therefore alternative therapies will be necessary to treat patients who present 
with active ESR1 fusions. Palbociclib, a selective CDK4/6 inhibitor was chosen for study 
because of our recent report that this agent can antagonize the growth of tumors expressing 
ESR1 mutations as long as phospho-Rb (pRb) is present (Wardell et al., 2015). Because the 
target of activated CDK4/6 is Rb, pRb levels were examined by immunohistochemistry 
(IHC) in ESR1 fusion-expressing T47D xenograft tumor sections (Figure S5A). pRb levels 
in YAP1 and PCDH11X fusion xenograft tumors grown without E2 supplementation were 
comparable with YFP controls +E2 and were elevated relative to YFP −E2 and NOP2 
fusion-containing tumors. T47D stable cells expressing YFP and the three in-frame ESR1 
fusions were treated with palbociclib under hormone-deprived conditions and growth-
inhibitory effects were assessed (Figure 5A). Palbociclib inhibited T47D cell growth driven 
by the YAP1 and PCDH11X fusions in a dose-dependent manner. A similar palbociclib 
effect was observed in ESR1 fusion-expressing MCF7 stable cells (Figure S5B). To test 
palbociclib sensitivity in vivo, a PDX model naturally harboring the ESR1-e6>YAP1 fusion 
(WHIM18) was exposed to palbociclib. Consistent with in vitro results, tumor growth in the 
PDX model was inhibited in mice treated with palbociclib compared with vehicle-treated 
mice (Figure 5B; tumor growth rates shown in Figure S5C). Palbociclib-treated WHIM18 
tumors also showed significant reduction in pRb and marked decrease in Ki-67 levels, 
without altering levels of ER (Figure 5C) or progesterone receptor (PR) (Figure S5D). Areas 
containing micrometastatic ER+ cells observed in the lungs of vehicle chow-treated 
WHIM18 mice were not seen in palbociclib-treated mice (Figure 5D), suggesting that 
pulmonary metastatic frequency could also be downregulated by CDK4/6 inhibition.
DISCUSSION
This study demonstrated that two in-frame ESR1 fusions in a small late-stage cohort of 
metastatic ER+ cases drive not only endocrine therapy resistance but also metastatic disease 
progression. The functional characterization of ESR1 fusions’ properties described herein 
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should drive efforts to identify and further characterize additional ESR1 fusions in early- and 
late-stage ER+ breast cancer.
The ability to block active ESR1 fusion-induced growth with a CDK4/6 inhibitor has 
important implications for clinical practice. Patients with active ESR1 fusions may present 
with a clinical pattern of rapidly progressing disease despite adjuvant or metastatic 
endocrine therapy treatment and therefore be offered chemotherapy instead of a CDK4/6 
inhibitor-containing regimen. Because therapeutically resistant disease is infrequently re-
biopsied and even more rarely analyzed using RNA-seq, a prospective study of ESR1 in-
frame fusion-expressing ER+ tumors will be required to establish an effective approach for 
these tumors.
Although ESR1 fusions are challenging to diagnose because of variable 3′ fusion partners, 
evidence for additional ESR1 fusions is emerging in the literature. For example, ESR1-
e6>DAB2 and ESR1-e6>GYG1 were both identified in metastatic ER+ breast cancer 
(Hartmaier et al., 2018). Like the active ESR1 fusions we describe herein, ESR1-e6>DAB2 
and ESR1-e6>GYG1 follow the same pattern (i.e., ESR1 exon 6 in-frame fusions with 3′ 
partners provided by inter-chromosomal translocation). Thus, this type of ESR1 fusion gene 
structure is most clearly linked to endocrine therapy resistance. Several precision medicine 
programs now include RNA-seq in their standard pipelines, and thus much more data on 
ESR1-e6 in-frame fusion prevalence should be available soon.
Because active ESR1 fusions induce pRb (Figure S5A), pRb might also be an appropriate 
marker to guide CDK4/6 inhibitor therapy and might provide strong pre-clinical rationale to 
potentially examine pRb levels in patients on Als to define populations for CDK4/6 
inhibition. This idea is supported by our previous report, in which the growth of endocrine-
refractory PDX tumors remained sensitive to CDK4/6 inhibition, as long as those tumors 
express pRb under estrogen-deprived growth conditions (Wardell etal., 2015).
The inactivity of the ESR1-e6>NOP2 fusion is surprising, as the expressed recombinant 
protein is stable. This demonstrates that not every in-frame ESR1-e6 fusion is active with 
respect to endocrine therapy resistance. The NOP2 fusion may have other biological 
properties that we were unable to detect in our experimental model systems. The out-of-
frame ESR1 fusions also had no growth-promoting properties but could also be active 
though novel mechanisms.
The role of active ESR1 fusions in promoting EMT-like gene expression changes follows a 
pattern associated with other members from a diverse family of cancer-associated gene 
fusion events. For example, the TMPRSS2-ERG fusion in prostate cancer has also been 
reported to directly regulate cell migration genes (Tian et al., 2014). Given the diverse 
structures of EMT-inducing ESR1 fusions revealed here with the study of just two, it is also 
possible that more EMT and motility-inducing transcription factor gene fusions remain to be 
discovered, and the formation of these could be primary drivers of metastasis.
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CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed and will be 
fulfilled by the Lead Contact Matthew J. Ellis (mjellis@bcm.edu).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell Lines
All cell lines were purchased from ATCC and cultured at 37°C in 5% CO2. All cell lines 
were authenticated and tested for mycoplasma. HEK293T and MDA-MB-231 cells were 
cultured in DMEM with L-Glutamine and 4.5 g/L glucose (HyClone) supplemented with 
10% FBS (cat# F0926, Sigma) and 1% penicillin-streptomycin (Invitrogen). T47D and 
MCF7 cells were cultured in RPMI1640 with L-Glutamine (Mediatech) supplemented with 
10% FBS, glucose to 4.5 g/L (Sigma), 10 mM HEPES (GenDEPOT), 1 mM sodium 
pyruvate (GenDEPOT), and 50 μg/mL gentamycin (GenDEPOT). Estrogen/hormone 
deprivation was performed by plating cells in culturing media overnight followed by 
washing with PBS and replacing with hormone deprived media consistaing of phenol red 
free media supplemented as described above but with 10% charcoal-stripped serum (CSS) 
(cat# F6765, Sigma), followed by changing with hormone-deprived media every 2-3 days 
for 5-7 days.
In Vivo Animal Studies
All animal experiments were carried out in strict accordance with the guidelines 
recommended for care and use of laboratory animals by the National Institutes of Health. 
The Animal Studies Committee at Washington University (St. Louis, MO, USA) approved 
all animal protocols used for T47D xenograft studies. Three-week old NOD/SCID gamma 
female mice were purchased from Jackson Laboratories. Stable T47D cells were trypsinized, 
counted, washed by PBS, and suspended in ice cold serum free RPMI medium at 10 × 106 
cells per 100 μL. Matrigel was added to a final 33% by volume. 150 μL mix (10×106 cells) 
was injected subcutaneously into the mouse flanks bilaterally. Six mice were injected per 
group. Tumor volumes were measured by caliper weekly. For PDX studies, all animal 
procedures were approved by the Institutional Animal Care and Use Committee at Baylor 
College of Medicine (Houston, TX, USA) (protocol# AN-6934). 2-3 mm tumor pieces from 
a second generation growing WHIM18 tumor were engrafted into cleared mammary fat pads 
of 3-4 weeks old SCID/bg mice (Charles River) and allowed to grow without exogenous E2 
supplementation until tumors reached 150-400 mm3. Mice were then randomized to receive 
vehicle or palbociclib (Pfzier) containing chow (daily dose of 70mg/kg per day) for an 
additional 30 days (11 mice per group). Tumor volumes were measured by caliper every 3-4 
days. For all animal experiments, tumor volumes were calculated by V = 4/3 × π × 
(length/2)2 × (width/2). Animals were sacrificed when tumors reached 1500 mm3 or at the 
study end time point. Tumors and organs were harvested and frozen in liquid nitrogen for 
storage or fixed in 4% formaldehyde overnight at RT, then held in 70% ethanol before 
paraffin embedding, sectioning (5 μm) and subsequent IHC processing.
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The primary breast cancer samples for this study were either accrued from two neoadjuvant 
endocrine therapy trials (Ellis et al., 2011; Olson et al., 2009) or analyzed from TCGA breast 
samples (Ciriello et al., 2015). The methodologies for RNA extraction and expression 
profiling experiments have been previously published (Ellis et al., 2011). Frozen metastatic 
biopsy samples from patients with advanced breast cancer (Table S2) were accrued under a 
banking protocol approved by the Washington University School of Medicine Institutional 
Review Board (approval number 201102244).
METHOD DETAILS
ESR1 Fusion Discovery Using ChimeraScan and INTEGRATE
Fusion candidates were discovered using ChimeraScan (Iyer et al., 2011) and INTEGRATE 
(Zhang et al., 2016) when whole genome sequencing data were available from 38 cases 
previously reported (Ellis et al., 2012). The Illumina RNA-Seq paired-end reads in FASTQ 
format were provided to ChimeraScan version 0.4.5, which was run using default 
parameters. The alignments (BAM format by TopHat2) of the RNA-seq reads are provided 
to INTEGRATE version 0.1, which is run using default parameters in RNA only mode. All 
the analysis was based on hg19. ChimeraScan results (bedpe format) are filtered by 
removing records with types marked as read through, overlapping converging, overlapping 
diverging, adjacent converging, and adjacent diverging. These could be transcriptome only 
variations or chimeras reported because of certain annotation issues. The gene fusions with 
ESR1 gene as a fusion partner are picked out from all the fusion candidates discovered by 
the methods described above and from analysis done by TCGA.
Molecular Cloning to Generate ESR1 Fusion Constructs
cDNAs encoding ESR1-e6>NOP2, ESR1-e6>PCDH11X, and ESR1-e6>AKR1D1 were 
synthesized from patient RNAs via oligo-dT reverse transcription (RT) followed by 
polymerase chain reaction (PCR) using primers complementary to the 5′ and 3′ ends of the 
fusion genes. ESR1-e7>POLH and ESR1-e6>AKAP12 were generated from cDNAs 
encoding ESR1, POLH, and AKAP12 by overlapping PCR extension/amplification as 
previously described for ESR1-e6>YAP1 (Li et al., 2013). All other constructs were created 
by standard PCR using pre-existing cDNA templates. Amplified DNA fragments were 
inserted into the lentiviral vector pFLRu-FH as described previously (Li et al., 2013). ESR1-
e6>AKAP12 was generated but due to its exceptionally large size, could not be cloned into 
the lentiviral vector and subsequently proved hard to express upon transfection and was not 
studied further. Carboxy-terminal HA-tagged ESR1 fusion constructs were generated by 
subcloning each construct from pFLRu-FH using primers for PCR that included BamHI and 
EcoRI restriction sites along with the HA sequence (STAR METHODS) into pCDH-CMV-
MCS-EF1α-RFP-Puro vector (System Biosciences). All constructs in their final vectors 
were confirmed by Sanger sequencing.
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Lentiviral Production and Stable Cell Line Generation
Lentiviral production was performed as described previously (Li et al., 2013). Briefly, ESR1 
constructs cloned in pFLRu-FH and HA-tagged ESR1 constructs in pCDH-CMV-MCS-
EF1α-RFP-Puro (System Biosciences) and pCDH-CMV-MCS-ER1α-Puro (System 
Biosciences) vector DNAs were co-transfected with the packaging plasmids into HEK293T 
cells using Fugene HD (Roche). Culture media containing viruses were harvested after 48 
hr, filtered, and added to T47D and MCF7 cells in the presence of polybrene. Stably infected 
cells were selected by 2 μg/mL puromycin (Sigma) two days after infection. Three sets of 
T47D stable cell lines were generated, one set expressing non-HA-tagged ESR1 constructs 
(used in Figures 2, S2, 4G, 4H, 5A, and S5A), one set expressing HA-tagged ESR1 
constructs in pCDH-CMV-MCS-EF1α-RFP-Puro (used in Figures 3, S3D-S3F, 4A-4F, and 
S4A-S4F) and one set expressing HA-tagged ESR1 constructs in pCDH-CMV-MCS-ER1α-
Puro used in Figure S3A. Two sets of MCF7 cells were generated, one set expressing non-
HA-tagged ESR1 constructs (used in Figures S2C, S2D, and S5B) and HA-tagged ESR1 
constructs in pCDH-CMV-MCS-ER1α-Puro (used in Figures 4D and S4G).
In Vitro Growth Assays
Hormone independent cell growth was subsequently measured by low density triplicate 
plating of T47D or MCF7 cell lines in hormone-deprived media in 96-well plates (2000 
cells/well) in the absence or presence of 10 nM E2 (Sigma) in combination without or with 
10 nM fulvestrant (Selleckchem). Cell growth was quantified by Alamarblue assay at Day 1 
and Day 12 post plating and relative growth was calculated as Day 12/Day 1 ratios. 
Remaining cells not used in the Alamarblue assay were plated in CSS containing media and 
grown further for 72h in the absence or presence of 10 nM fulvestrant before harvesting and 
subsequent processing for immunoblot analysis. For palbociclib sensitivity assays, T47D 
and MCF7 cells were hormone deprived for seven days, then plated in 96-well plates as 
described above in the absence of presence of 3-fold dilutions of palbociclib (cat# S1116, 
Selleckchem) from 10 μM down to 0.0015 μM for 12 days, changing hormone-deprived 
media and palbociclib every 2-3 days. Cell growth was quantified similarly as above and 
relative growth was calculated by taking the palbociclib treated Day 12/Day 1 ratio divided 
by the vehicle treated Day 12/Day 1 ratio.
siRNA Knockdown
Stable T47D or MCF7 were hormone-deprived for 7-9 days before pre-treatment with 
DMSO vehicle or 1 μM fulvestrant for 24h prior to reverse transfection with RNAiMAX 
(Invitrogen) and 50 nM siRNA Universal Negative Control #1 (cat# SIC001, Sigma) or 50 
nM siESR1 targeting N-terminal sequences of ESR1 (Sigma). Fresh DMSO or 1 μM 
fulvestrant was added during the transfection. 48h post transfection, cells were collected by 
scraping and subjected to immunoblotting.
Immunoprecipitation and Immunoblot Analysis
For IP assays, hormone deprived stable T47D cells were left untreated or stimulated with 10 
nM E2 for 15’ at 37°C. Cells were harvested then lysed in IP lysis buffer [0.5% NP-40, 10% 
glycerol, 280 mM NaCl, 50 mM Tris pH 8.0, 2 mM EGTA, 0.2 mM EDTA, 1 mM PMSF, 1 
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mM sodium orthovanadate, 1 mM DTT, 1 μg/mL pepstatin, phosSTOP phosphatase 
inhibitor tablet (Roche), and complete EDTA-free protease inhibitor tablet (Roche)] for 20 
min. 0.5 mg of clarified lysates were immunoprecipitated with an Anti-HA antibody (cat# 
3724, Cell Signaling, 1:50) overnight at 4°C with rotation. Protein A magnetic beads (cat# 
1614013, Bio-Rad) were added and rotated for 1h at 4°C followed by extensive washing 
with IP lysis buffer. Immunoprecipitated samples along with 25 μg of whole cell lysates 
(inputs) were heated at 90°C before loading onto SDS-PAGE gels (Invitrogen) and 
electroblotted onto nitrocellulose membranes (Bio-Rad). Whole cell lyates for all other 
immunoblotting procedures were prepared in RIPA buffer and blotted as described 
previously (Li et al., 2013). Fresh frozen WHIM18 tumors were cryopulverized (Covaris 
CP02) then lysed in RIPA buffer. The following primary antibodies were used for blotting: 
N-terminal estrogen receptor α (cat# 04-820, Millipore, 1:1000), C-terminal estrogen 
receptor α (cat# sc-543, Santa Cruz, 1:1000), E-Cadherin (cat#14472, Cell Signaling, 
1:1000), and Snail (cat #3879, Cell Signaling, 1:500). β-Actin (cat# A5316, Sigma, 1:5000) 
used as loading control for all immunoblots.
Dual Luciferase ERE Reporter Assay
To test ER fusion effect on wild-type ERE activation ability, 60 ng of empty pCDH-CMV-
MCS-ER1α-Puro Vector, ESR1-WT-HA, ESR1-e6>YAP1-HA, ESR1-e6>PCDH11X-HA, 
ESR1-e6>NOP2-HA, ESR1-e6-HA, or ESR1-Y537S-HA were co-transfected by reverse 
transfection using Lipofectamine 2000 (Invitrogen) together with 25,000 hormone-deprived 
HEK293T cells per well in triplicates in a 96-well plate with 60 ng Firefly luciferase 
reporter vector (driven by three copies of vitellogenin Estrogen Response Element (11354, 
Addgene) (Hall and McDonnell, 1999) and 5 ng control Renilla luciferase vector (pGL4.70, 
Promega). Prior to transfection, HEK293T cells were cultured in hormone deprived media 
containing charcoal-stripped serum for seven days. One day after transfection, cells were 
either left unstimulated or stimulated with 2.5 nM E2 for 24h. On the following day, cells 
were quantified for the firefly and Renilla luciferase levels using the Dual-Glo Luciferase 
assay kit (Promega). Averages of Firefly/Renilla luminescence readings from each sample 
were calculated and expressed as fold change in activity relative to Vector transfected −E2.
Biotinylated 3X ERE Pulldown
All 5′ biotinylated DNA were synthesized by Integrated DNA Technologies. The sequence 
of the wild-type and mutant 3XERE were 
GTAGGTCACTGTGACCTAGACGCAGGTCACTGTGACCTAGACGCAGGTCACTGTGACCGT and 
GTAGATCACTGTGAACTAGA CGCAGATCACTGTGAACTAGACGCAGATCACTGTGAACGT, 
respectively. Each DNA and its complement were annealed by boiling at 95°C for 15 min 
and allowed to cool overnight at room temperature. Each biotinylated DNA was bound to 
streptavidin M-280 Dynabeads (Invitrogen) per manufacturer’s directions and washed with 
NETN buffer (20 mM Tris, pH 8.0,150 mM NaCl, 0.5mM EDTA, and 0.5% NP-40) before 
incubation with 200-1000 μg of HEK293T extracts (whole cell or nuclear extracts) 
transiently transfected with the indicated expression constructs. Protein/DNA extracts were 
rotated at 4°C for 1h then washed four times with NETN buffer and analyzed by 
immunoblotting.
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Chromatin preparation—Stable T47D cells were hormone deprived for 7 days in 
charcoal-stripped containing media before fixing at 1% formaldehyde (cat# F8775, Sigma) 
while swirling for 10 min at RT. To quench, glycine was added to 0.2 M and incubated for 
another 5 min at RT. Cells were then washed and harvested in cold TBSE (20 mM Tris-HCl 
pH 7.5, 150 mM NaCl, 1 mM EDTA). After further washing in TBSE, cells were lysed in 
0.1% SDS buffer (50 mM HEPES-KOH pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% Triton 
X-100, 0.1% sodium deoxcholate, 0.1% SDS, cOmplete EDTA-free protease inhibitor 
cocktail tablet) for 15 min at 4°C with rotation. Samples were centrifuged and washed 3X 
with 0.1% SDS buffer and resultant nuclear pellets were lysed with 1% SDS buffer for 15 
min at 4°C with rotation. After washing with 0.1% SDS buffer, nuclear lysates were 
centrifuged at 20,000 rpm and resultant chromatin pellets were resuspended in 0.1% SDS 
buffer with 0.5 mm glass beads (cat# 11079105, Biospec). The chromatin solution was 
sonicated with a Branson Sonifier S450D with 18, 30 s pulses at 40% amplitude. Crosslinks 
were reversed by incubating sonicated chromatin with pronase (Roche) at 42°C for 2h 
followed by incubation at 67°C for 6h. Phenol:chloroform (Ambion) extraction was used to 
isolate sonicated chromatin that contained DNA fragments 200-500 bp in size that was 
confirmed by agrose gel electrophoresis.
Chromatin immunoprecipitation—Dynabeads Protein G (ThermoFisher) were 
equilibrated in 0.1% SDS buffer then a portion was added to chromatin extracts from above 
to pre-clear for 2h at 4°C with rotation. HA antibody (cat# sc-7392, Santa Cruz) was added 
to the remaining Protein G and allowed to bind for 2h at 4°C with rotation. Pre-cleared 
chromatin extracts were then added to antibody-bound beads and rotated overnight at 4°C 
followed by extensive 5 min washes 0.1% SDS buffer, then once in 0.1% SDS buffer 
containing 0.35 M NaCl, then once in ChIP wash buffer (10 mM Tris-HCl pH 8.0, 250 mM 
LiCl, 1 mM EDTA, 0.5% NP-40, 0.5% sodium deoxycholate), then once in TE buffer. 
Elution was performed by pelleting and resuspending in ChIP buffer and heating at 68°C for 
1h with agitation. Samples were pelleted, reuspended in TE buffer and crosslinks were 
reversed with pronase and heating at 42°C for 2h followed by incubation at 67°C overnight. 
Chromatin isolation was then performed using phenol:chloroform extraction and used for 
ChIP-qPCR and subsequently processed for next generation sequencing as follows:
Next generation sequencing—The Biopolymers Facility (Harvard Medical School, 
Boston, MA, USA) conducted quality control testing on an Angilent BioAnalyzer followed 
by Wafergen PrepX DNA ChIP library preparation. Pooled libraries were loaded onto two 
lanes of HiSeq Rapid v2 flow cell (Illumina) with PhiX control adaptor-ligated library 
(Illumina) spiked-in at 5% by weight to ensure balanced diversity and to monitor clustering 
and sequencing performance. Single-end 50 bp reads were generated on a HiSeq 2500 
Sequencing System.
RNA-seq—Stable T47D cells were hormone deprived for 5 days in charcoal-stripped 
containing media then grown for another 48h in the absence or presence of 10 nM E2. RNA 
was isolated using RNeasy Mini Kit (QIAGEN) according to manufacturer’s directions and 
subjected to on column DNase (QIAGEN) digestion to remove genomic DNA before final 
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elution in water. The Genomic and RNA Profiling Core (Baylor College of Medicine, 
Houston, TX, USA) conducted sample quality checks using the NanoDrop 
spectrophotometer and Agilent Bioanalyzer 2100 followed by subsequent Illumina TruSeq 
Stranded mRNA library preparation protocol (p/n 15031047, rev. E) as follows: A double-
stranded DNA library was created using 180ng of total RNA (measured by picogreen), with 
the Illumina TruSeq Stranded mRNA-Seq Sample Prep kit (cat# RS-122-2101). First, cDNA 
was created using the fragmented 3′ poly(A) selected portion of total RNA and random 
primers. During second strand synthesis, dTTP is replaced with dUTP which quenches the 
second strand during amplification, thereby achieving strand specificity. Libraries were 
created from the cDNA by first blunt ending the fragments, attaching an adenosine to the 3′ 
end and finally ligating unique adapters to the ends. The ligated products were then 
amplified using 15 cycles of PCR. The resulting libraries were quantified using a NanoDrop 
spectrophotometer and fragment size assessed on an Agilent Bioanalyzer. A qPCR 
quantification was performed on the libraries to determine the concentration of adaptor 
ligated fragments using Applied Biosystems ViiA7 Real-Time PCR System and a KAPA 
Library Quant Kit (cat# KK4824).
Using the concentration from the ViiA7 qPCR machine above, 27 pM of library was loaded 
onto two lanes of a high output v4 flowcell (Illumina p/n PE-401-4001) and amplified by 
bridge amplification using the Illumina cBot machine (cBot protocol: 
PE_HiSeq_Cluster_Kit_v4_cBot_recipe_v9.0). PhiX Control v3 adaptor-ligated library 
(Illumina p/n 15017666) is spiked-in at 2% by weight to ensure balanced diversity and to 
monitor clustering and sequencing performance. Paired-end 100 bp reads were generated on 
a HiSeq 2500 Sequencing System (Illumina p/n FC-401-4003).
Quantitative PCR—qPCR was performed using SsoAdvanced SYBR green Supermix 
(Bio-Rad) and 0.5 mM primers (Sigma) listed in Key Resources Table and run on a 
LightCycler 96 (Roche). All samples were run in triplicate and values shown are the average 
± SEM of at least 2 independent experiments. For ChIP-qPCR, 1% inputs were run for each 
corresponding sample and primers against a region on Chr20 which ERα does not bind was 
used as a negative control. Chromatin captured from HA-ChIP in YFP-HA cells were used 
as control instead of IgG antibody alone. For mRNA-qPCR (Figures 3D, S3F, 4C, and S4B), 
RNA was extracted as described above from stable T47D cells grown in hormone deprived 
media for 5 days, before growing another 24h in the absence (−E2) or presence of 10 nM E2 
and/or 1 μM fulvestrant as indicated. One step quantitative RT-PCR was performed using 
iScript reverse transcriptase (Bio-Rad) with 25 ng RNA. Expression was normalized to 
GAPDH and relative expression was calculated as fold change using the 2−ΔΔCt method with 
YFP −E2 set to 1.
Immunohistochemistry—IHC staining was performed with assistance from The Lester 
and Sue Smith Breast Center Pathology Core at Baylor College of Medicine (Houston, TX, 
USA). Tissue sections were incubated at 58°C overnight in a dry slide incubator and 
deparaffinized in xylene and graded alcohol washes. Antigen retrieval was performed in 0.1 
M Tris-HCl pH 9.0 following by quenching in 3% H2O2. The following antibodies were 
used to stain for 1h at RT: ERa (clone 6F11, Novocastra, 1:200), pRb (Ser780) (clone 
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D59B7, Cell Signaling, 1:25), Ki67 (clone MIB-1, Dako, 1:200), and PR (clone PgR 1294, 
Dako, 1:1600). After washing in TBS, EnVision labeled polymer-HRP antimouse or anti-
rabbit antibodies (Dako) were added for 30 min. at RT. Slides were washed with TBS then 
developed with DAB+ solution (Dako) and DAB sparkle enhancer (Biocare). After washing 
in TBS, slides were counstained with Hematoxylin, dehydrated, and cleared before 
coverslipping with Cytoseal (VWR). ER positive staining cells were quantified in lung 
sections from 5 T47D xenograft bearing mice. Stained WHIM18 tumor and lung sections 
were quantified from 5 mice per treatment group.
Scratch Wound Assay—Stable T47D cells were hormone deprived for 7 days before 
seeding in hormone deprived media at 50,000 cell/well in a 96-well ImageLock plate (Essen 
BioScience). The following day, cells were treated 10 μg/mL mitomycin C (Sigma) for 2h 
before wounding with a WoundMaker (Essen BioScience). Cells were washed with hormone 
deprived media then fresh hormone deprived media containing mitomycin C was added. 
Images were acquired every 3h for 72h with an IncuCyte live-cell analysis system (Essen 
BioScience). Fresh hormone deprived media plus mitomycin C was changed every 24h. Cell 
motility assessed by the relative wound density (RWD) calculated by measuring density in 
the wound area relative to the density outside the wound area at 72h. The RWD is 0% at 0h 
and 100% when the density inside the wound is the same as the density outside the wound, 
therefore normalizing for changes in density due to proliferation outside the wound. 
Representative images are depicted and quantification from average of three independent 
experiments ± SEM are shown. P-values based on ANOVA followed by Dunnett’s post hoc 
test for multiple comparisons correction.
Immunofluorescence Microscopy—Hormone deprived stable T47D cells were seeded 
onto poly-D-lysine coated coverslips (Fisher) and grown overnight. Cells were fixed with 
4% formaldehyde for 20 min. at RT followed by permeabilization with 0.2% Triton X-100 
for 10 min at RT and blocking with 10% normal goat serum for 1h. Antibodies against E-
cadherin (cat# 14472, Cell Signaling, 1:50), vimentin (cat# 5741, Cell Signaling, 1:100) or 
HA-tag (cat# 2367, Cell Signaling, 1:50) were incubated overnight at 4°C then goat anti-
mouse-488 (cat# A-11011, Invitrogen, 1:1000), goat anti-rabbit-488 (cat# A-11008, 
Invitrogen, 1:1000), or goat anti-mouse-568 (cat# A-11004, Invitrogen, 1:1000) was added 
for 30 min at RT. Coverslips were mounted onto slides with ProLong Gold Antifade Reagent 
(Invitrogen). Fluorescence images were acquired on a Nikon Eclipse Ti microscope 
equipped with a CoolSNAP EZ camera (Photometrics Scientific) using a Plan Apo 40X/0.95 
aperture objective and Nikon NIS elements software. Images were quantified with ImageJ 
by setting a threshold from E-cadherin fluorescence channel from ESR1-WT cells which 
gave cell surface appearance. The same threshold was applied to images acquired from all 
other cell lines and cells were considered E-cadherin+ when cell surface signal was present 
using the described threshold. 2-3 images per cell line were quantified and shown are 
averages from two independent experiments ± SEM.
QUANTIFICATION AND STATISTICAL ANALYSIS
All statistical tests were performed with GraphPad Prism 7. P-values less than 0.05 were 
considered statistically significant (*p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001). For 
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box and whiskers plots, the box depicts interquartile range with median line and whiskers 
extending to minimum and maximum values for each group.
Immunofluorescence images were quantified with ImageJ by setting a threshold from E-
cadherin fluorescence channel from ESR1-WT cells which gave cell surface appearance. 
The same threshold was applied to images acquired from all other cell lines and cells were 
considered E-cadherin+ when cell surface signal was present using the described threshold. 
2-3 images per cell line were quantified and shown are averages from two independent 
experiments ± SEM.
For cell proliferation assays, significance was determined based on one-way ANOVA 
followed by Tukey’s post hoc test for multiple comparisons correction for ESR1-e6>YAP1 
or ESR1-e6>PCDH11X fusion-expressing cells compared to all other stable T47D cells 
within a treatment group (indicated by asterisks) or using two-way ANOVA followed by 
Bonferonni’s post hoc test for multiple comparisons correction for each construct after E2 
stimulation, +E2 versus −E2 (#### p < 0.0001). Data are mean ± SEM of three independent 
experiments. For palbociclib sensitivity assays in stable T47D and MCF7 cell lines, each 
point represents averages ± SEM from 3-4 independent experiments of relative cell growth 
for indicated palbociclib dose, calculated by taking the palbociclib treated Day 12/Day 1 
alamarBlue reading ratio divided by vehicle treated Day 12/Day 1 ratio. P-values describes 
significance between YFP +E2, ESR1-e6>YAP1, and ESR1-e6>PCDH11x slopes compared 
to YFP −E2 as measured by ANOVA with Tukey’s post hoc analysis for multiple 
comparisons.
For ChIP-qPCR assays, bar graphs depict enrichment of ER binding regions in hormone 
deprived stable T47D cells before and after stimulation with E2 (100 nM) for 45 min as 
determined by HA-ChIP followed by qPCR for ER binding regions of estrogen responsive 
genes as indicated and negative ER binding region. Average values from 3 experiments are 
shown ± SEM. Asterisks denote significant differences in binding compared to WT-ER −E2 
for each gene binding region as determined by ANOVA followed by Tukey’s post hoc test.
In Vivo Analysis
For T47D xenograft assays, significance of tumor volumes Day 146 post injection was 
determined based on Kruskal-Wallis test followed by Dunn’s post hoc analysis for multiple 
comparisons correction comparing YFP −E2 to all other groups with N = 6 mice per group. 
For ER+ cell counting in the lungs, ER+ cells from IHC images of 5 mice bearing 
xenografted tumors at Day 146 were manually counted. Statistical analysis was based on 
Kruskal-Wallis test with Dunn’s post hoc analysis for multiple comparisons correction 
comparing YFP versus fusion-bearing groups and YFP +E2.
For WHIM18 PDX assays, Figure 5B depicts averages of tumor volumes from 8-11 mice 
per group ± SEM are shown. P-value determined by unpaired t test describes significance of 
tumor growth rates (slopes) derived from tumor volumes at day of randomization/start of 
treatment (Day 61 post transplantation) to experiment end (Day 91 post transplantation) for 
vehicle and palbociclib treated mice. Figure S5C depicts tumor growth rates as described 
above for all tumors measured in each condition. Middle line represents mean tumor volume 
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± SD. Day 0 post treatment is the same as treatment start/Day 61 post transplantation and 
represents the tumor growth rate from time tumors were palpable (Day 49 post 
transplantation) up to treatment start date. Day 30 is the same as Day 91 post transplantation 
and represents on-treatment tumor growth rates. P-values determined by one-way ANOVA 
with Tukey’s post hoc analysis for multiple comparisons. For IHC images, positive staining 
cells were quantified in tumor and lung sections from 5 mice per treatment group. Bar 
graphs represents mean ± SD and P-values indicate significance as determined by Wilcoxon 
rank-sum tests.
ChIP-seq Analysis
Single-end 50 bp reads were aligned to hg19 (GRCh37) reference genome using BWA(Li 
and Durbin, 2010) and alignment files were converted to BED format using BEDTools 
(Quinlan and Hall, 2010). BED files were used for peak calling by MACS v1.4.2 (Zhang et 
al., 2008). MACS peaks (p < 1e−7 cutoff and associated FDRs) were annotated with GREAT 
(McLean et al., 2010) using default settings. Motif analysis was performed by taking ~100 
bp sequences centered on the summit of peaks and submitted for enrichment analysis using 
MEME-ChIP in normal mode (Bailey and Elkan, 1994). P-values represents the probability 
that an equal or better site would be found in a random sequence of the same length 
conforming to the background letter frequencies (Bailey and Elkan, 1994).
RNA-seq Analysis
Paired-end 100 bp reads were aligned to hg19 (GRCh37) reference genome using RSEM 
v1.2.31 (Li and Dewey, 2011) and Bowtie 2 (Langmead and Salzberg, 2012). TPM 
(Transcripts Per Million) values calculated by RSEM were log2 transformed and row Z-
scores were generated for the all heatmaps shown. Differential gene expression analysis was 
performed using EBseq (Leng et al., 2013) with FDR < 0.1 as a cutoff comparing 4 groups: 
(1) YFP +E2 versus YFP −E2, (2) ESR1-e6>YAP1 −E2 versus YFP −E2, (3) ESR1-
e6>PCDH11X −E2 versus YFP −E2, and (4) ESR1-e6>NOP2 −E2 versus YFP −E2. 
Hierarchal clustering was performed on differentially expressed genes for which a nearby 
binding site within 1 Mb was observed by ChIP-seq shared by ESR1-WT, ESR1-e6>YAP1, 
ESR1-e6>PCDH11X, and ESR1-e6>NOP2 for Figure 3C. Clustering was also performed on 
differentially expressed genes for which a nearby site within 1 Mb was selectively bound by 
both ESR1-e6>YAP1 and ESR1-e6>PCDH11X but bound by ESR1-WT nor ESR1-
e6>NOP2 (Figure S4C).
DATA SOFTWARE AND AVAILABILITY
The accession number for the ChIP and RNA sequencing data from T47D reported in this 
paper is GEO: GSE116170. TCGA data for fusion gene discovery and for gene expression 
analysis can be downloaded from https://portal.gdc.cancer.gov/ and https://
portal.gdc.cancer.gov/legacy-archive. RNA-seq of human primary breast tumors from two 
neoadjuvant aromatase inhibitor clinical trials can accessed through dbGaP phs000472.
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• ESR1 fusions drive ligand-independent growth and endocrine therapy 
resistance
• ESR1 fusions reprogram the ER cistrome to drive EMT and metastasis
• CDK4/6 inhibition suppresses ESR1 fusion-induced growth
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Figure 1. Identification and Verification of ESR1 Fusions
(A) Circos plot depicting ESR1 fusion events from Table S1. In-frame ESR1 fusions are 
depicted with a red line, and out-of-frame ESR1 fusions depicted with a blue line. Asterisks 
denote PCR-validated transcripts (Figure S1).
(B)Of eight ESR1 fusions identified in (A) that were PCR validated, only three ESR1 
fusions produced stable, in-frame proteins (indicated in red): ESR1-e6>YAP1, ESR1-
e6>PCDH11X, and ESR1-e6>NOP2. Illustration depicting in-frame ESR1 fusions with 
ESR1 codon structure shown at the bottom. Non-coding exons (e) 1 and 2 are shown as 
white boxes, and gray boxes depict exons encoding domains shown above. Vertical line 
indicates shared break points after exon 6 of ESR1. All depicted fusions retain exons 
encoding amino acids (aa) 1–365 of ER corresponding to the activation function 1 (AF1) 
domain, DNA-binding domain (DBD), the hinge region that includes the nuclear localization 
domain, and part of the activation function 2 (AF2)/ligand-binding domain (LBD).
(C)RNA-seq determined rank-ordered expression of YAP1, PCDH11X, and NOP2 from 728 
TCGA breast tumor samples, shown as colored circles according to subtype. Triangles 
indicate ranked expression from indicated ESR1 fusion containing sample among the TCGA 
breast samples.
See also Figure S1.
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Figure 2. In-Frame ESR1 Fusions from Endocrine-Refractory Disease Confer Estrogen-
Independent and Fulvestrant-Resistant Growth of ER+ Breast Cancer Cells
(A) RNA-seq mapped read depth was calculated across YAP1, PCDH11X, and NOP2 genes 
in corresponding fusion containing tumors. Red line indicates fusion breakpoints.
(B) Immunoblotting with an N-terminal ER antibody in hormone-deprived stable T47D and 
WHIM18 PDX. Asterisks indicate ER fusion.
(C) Cell proliferation studies of hormone-deprived stable T47D cells (−E2), after fulvestrant 
treatment (−E2, +Fulvestrant), after E2 stimulation (+E2), or after E2 stimulation with 
fulvestrant treatment (+E2, +Fulvestrant). Bar graphs show average ± SEM from three 
independent experiments. ****p < 0.0001 and ####p < 0.0001 as described in STAR 
Methods.
(D) Box and whisker plots show tumor volumes of T47D xenograft tumors grown with 
(+E2) or without E2 supplementation (−E2). Boxes depict interquartile range, center line 
represents median, and whiskers extend to minimum and maximum values for each group (n 
= 6). p values show significance comparing YFP −E2 to all other groups.
See also Figure S2.
Lei et al. Page 24













Figure 3. Active ESR1 Fusions Promote Estrogen-Independent Expression of Target Genes
(A) Venn diagram depicting overlap of binding sites from hormone-deprived stable T47D 
cells expressing HA-tagged ESR1 constructs identified by HA-ChIP-seq.
(B) HA-ChIP followed by qPCR for ER-binding regions of ER-responsive genes and 
negative ER-binding region. Bar graphs show average values from three experiments ± 
SEM. Asterisks denote significant differences as described in STAR Methods.
(C) Heatmap showing differentially expressed genes near 445 sites bound by ESR1-
e6>YAP1, ESR1-e6>PCDH11X, and ESR1-WT identified in (A). Known ER-responsive 
genes are indicated (CTSD, GREB1, PGR, TFF1, and PDZK1). Scale bar indicates row Z 
score.
(D) Bar graphs depicting relative fold changes of estrogen-responsive genes whose ER-
binding regions were examined in (B) from hormone-deprived stable T47D cells, 
normalized to YFP −E2 (dark blue bar), after E2 addition (+E2, red bar), or in combination 
with fulvestrant (light blue and pink bars). −E2 and +E2 for ESR1 fusion-expressing cells 
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have been omitted for clarity; see Figure S3F for complete data. Data are shown as averages 
from two independent experiments ± SEM.
See also Figure S3.
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Figure 4. Active ESR1 Fusions Promote Metastasis by Upregulating an EMT-like Transcriptional 
Program
(A) Heatmap depicting genes upregulated by ESR1-e6>YAP1 and ESR1-e6>PCDH11X 
versus YFP and ESR1-e6>NOP2 (from bottom of Figure 3C). Scale bar indicates row Z 
score.
(B) GSEA using genes identified in (A). (C) Bar graphs depicting expression of SNAI1 and 
VCAN, by mRNA-qPCR in hormone-deprived stable T47D cells (−E2). Values are 
normalized to YFP −E2 (dark blue bar), treated with E2 (+E2, red bar), and in combination 
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with fulvestrant (light blue and pink bars). −E2 and +E2 conditions for all cell lines are 
shown in Figure S4B. Data are averages of two independent experiments ± SEM.
(D) Immunoblotting for endogenous ER (ER) and ER fusion (asterisks) using an N-terminal 
ERα antibody, Snail, and E-cadherin in hormone-deprived stable T47D and MCF7 cells. 
Vertical line in E-cadherin blot indicates different exposures taken for T47D and MCF7.
(E) Scratch wound healing assay images of hormone-deprived stable T47D at 0 and 72 hr 
post-wounding. Dotted black line indicates leading edge of cells. Scale bar, 300 μm.
(F) Immunoblotting of hormone-deprived T47D cells pre-treated with vehicle (Fulv−) or 
fulvestrant (Fulv+) before transfecting negative control siRNA (siRNA−) or siRNA against 
the N terminus of ESR1 (siESR1+).
(G) Immunoblotting for Snail in T47D xenograft and WHIM18 PDX tumors. (H) ER IHC 
images performed on lungs of mice bearing T47D xenografted tumors from Figure 2D. Box 
and whiskers plots show IHC quantification of ER+ cells, with boxes depicting interquartile 
range, center line representing median value, and whiskers extending to minimum and 
maximum values for each group (n=5). p values indicate significance comparing YFP −E2 
versus fusion-bearing groups or versus YFP +E2. Scale bar, 100 μm.
See also Figure S4 and Table S3.
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Figure 5. Growth Driven by ESR1 Fusions Can Be Suppressed with CDK4/6 Inhibitor Treatment
(A) Growth of hormone-deprived stable T47D cells in response to increasing concentrations 
of a CDK4/6 inhibitor, palbociclib. YFP +E2 used as control. P value describes significance 
between YFP +E2, ESR1-e6>YAP1, and ESR1-e6>PCDH11x slopes compared with YFP 
−E2. Data shown are averages of three independent experiments ± SEM.
(B) Tumor volumes of WHIM18 PDX in the absence of exogenous E2 supplementation. 
Arrow indicates treatment start (Tx) with vehicle or palbociclib containing chow. P value 
describes significance of tumor growth rates (slopes) derived from tumor volumes at day of 
randomization to experiment end. Data are shown as averages from 8–11 mice per treatment 
group ± SEM.
(C) Representative IHC images for ER, pRb, and Ki-67 from vehicle and palbociclib-treated 
WHIM18 tumors. Quantification of IHC staining below with significance comparing 
treatment groups. Data are averages counts from five tumor sections from each treatment 
group, with error bars representing SD.
(D) ER IHC images of lungs from WHIM18-bearing mice. Micrometastatic ER+ lesions 
were quantified by measuring area of ER+ cells. Data are shown as average ER+ areas from 
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five lung sections per treatment group. P value determined as in (C). Scale bar, 100 μm in 
(C) and (D).
See also Figure S5.
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KEY RESOURCES TABLE
REAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
Rabbit monoclonal anti-HA (clone 
C29F4)
Cell Signaling Technology Cat#3724; RRID:AB_1549585
Mouse monoclonal anti-HA (clone 
6E2)
Cell Signaling Technology Cat#2367; RRID:AB_331789
Mouse monoclonal anti-HA (clone 
F-7)
Santa Cruz Biotechnology Cat#sc-7392; RRID:AB_627809
Rabbit monoclonal anti-ERα (clone 
60C), N-terminal
Millipore Cat#04-820; RRID:AB_1587018
Rabbit polyclonal anti-ERα, C-
terminal
Santa Cruz Biotechnology Cat#sc-543; RRID:AB_631471
Mouse monoclonal anti-ERα (clone 
6F11)
Leica Microsystems Cat#NCL-L-ER-6F11; RRID:AB_563706
Mouse monoclonal anti-β-Actin Sigma-Aldrich Cat#A5316; RRID:AB_476743
Mouse monoclonal anti-E-Cadherin 
(clone 4A2)
Cell Signaling Technology Cat#14472; RRID:AB_2728770
Rabbit monoclonal anti-Vimentin 
(clone D21H3)
Cell Signaling Technology Cat#5741; RRID:AB_10695459
Rabbit monoclonal anti-Snail (clone 
C15D3)
Cell Signaling Technology Cat#3879; RRID:AB_2255011
Rabbit monoclonal anti-Phospho-Rb 
(Ser780) (clone D59B7)
Cell Signaling Technology Cat#8180; RRID:AB_10950972
Mouse monoclonal anti-Ki-67 
(MIB-1) (clone Ki-67)
Beckman Coulter Cat#IM1316; RRID:AB_131615




WHIM18 patient-derived xenograft 
(PDX)
Li et al., 2013 N/A
Chemicals, Peptides, and Recombinant Proteins
β-Estradiol (E2) Sigma-Aldrich Cat#E4389
Fulvestrant Selleckchem Cat#S1191
Pablociclib Pfzier and Selleckchem N/A and Cat#1116
Critical Commercial Assays




Human reference genome NCBI 
build 37, GRCh37
Genome Reference Consortium http://www.ncbi.nlm.nih.gov/projects/genome/assembly/grc/human
WGS and RNA-seq of WHIM18 
PDX
Li et al., 2013 dbGaP: phs000611
RNA-seq of human primary breast 
tumors from TCGA
Ciriello et al., 2015 https://portal.gdc.cancer.gov/ and https://portal.gdc.cancer.gov/legacy-archive
RNA-seq of human primary breast 
tumors from two neoadjuvant 
Olson et al., 2009 and Ellis et 
al., 2011
dbGaP: phs000472
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aromatase inhibitor clinical trials 
(Z1031/POL)
ChIP-seq and RNA-seq from T47D 
cell lines
This paper GEO: GSE116170
Experimental Models: Cell Lines
Human: HEK293T ATCC CRL-3216
Human: T47D ATCC HTB-133
Human: MCF7 ATCC HTB-22
Experimental Models: Organisms/Strains
NOD-SCID-IL2Rγc−/− mice Jackson Laboratories Cat#005557
Fox Chase SCID Beige mice Charles River N/A
Oligonucleotides
See Table S4 for sequences of 




pFLRu-FH Li et al., 2013 N/A
pCDH-CMV-MCS-EF1α-RFP+Puro System Biosciences Cat#CD516B-2
pCDH-CMV-MCS-EF1α-Puro System Biosciences Cat#CD510B-1
3X ERE TATA luc Hall and McDonnell, 1999 Addgene Plasmid Cat#11354
pGL4.70[hRluc] Promega Cat#E6881; GenBank AY738226
Software and Algorithms
BWA Li and Durbin, 2010 N/A
BEDTools Quinlan and Hall, 2010 N/A
GREAT McLean et al., 2010 N/A
MEME-ChIP Bailey and Elkan, 1994 N/A
RSEM 1.2.31 Li and Dewey, 2011 N/A
Bowtie 2 Langmead and Salzberg, 2012 N/A
EBseq Leng et al., 2013 N/A
GraphPad Prism 7 GraphPad Software N/A
ImageJ NIH https://imagej.nih.gov/ij/
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